Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study

Coupland, Carol A.C.; Hill, Trevor; Dening, Tom; Morriss, Richard; Moore, Michael; Hippisley-Cox, Julia

doi:10.1001/jamainternmed.2019.0677

All Outputs (5)

A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study (2024)
Journal Article
Ng, C., Dellschaft, N. S., Hoad, C., Marciani, L., Spiller, R., Crooks, C., …Smyth, A. R. (2024). A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study. NIHR Open Research, 3, Article 65. https://doi.org/10.3310/nihropenres.13510.2

Background
People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve lung funct... Read More about A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study.

Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis (2022)
Journal Article
Cianci, N., Subhani, M., Hill, T., Khanna, A., Zheng, D., Sheth, A., …Aithal, G. P. (2022). Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. World Journal of Hepatology, 14(5), 1025-1037. https://doi.org/10.4254/wjh.v14.i5.1025

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) represents a growing public health concern, with patients having higher risk of morbidity and mortality. It has a considerably high prevalence in the general population, estimated 20%-40% in Europe... Read More about Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Editorial Comment: Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control (2020)
Journal Article
Coupland, C. A., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2020). Editorial Comment: Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control. International Braz J Urol, 46(2), 283-284. https://doi.org/10.1590/S1677-5538.IBJU.2020.02.10

Re: Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case Control Study (2019)
Journal Article
Wein, A. J., Coupland, C. A. C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019). Re: Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case Control Study. Journal of Urology, The, 202(6), 1103-1104. https://doi.org/10.1097/01.ju.0000585420.46543.d2

Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study (2019)
Journal Article
Coupland, C. A., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019). Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Internal Medicine, 179(8), 1084-1093. https://doi.org/10.1001/jamainternmed.2019.0677

IMPORTANCE Anticholinergic medicines have short-term cognitive adverse effects, but it
is uncertain whether long-term use of these drugs is associated with an increased risk of dementia.

OBJECTIVE To assess associations between anticholinergic dr... Read More about Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study.